Industrial Transformation Research Hubs - Grant ID: IH150100028
Funder
Australian Research Council
Funding Amount
$3,708,510.00
Summary
ARC Research Hub for Integrated Device for End-user Analysis at Low-levels. ARC Research Hub for Integrated Device for End-user Analysis at Low-levels. This hub aims to improve detection of biological materials by building a portable device for rapid, time-critical detection of low-abundance molecular and cellular analytes. It is expected that the resulting technologies would be used at medical points of care, ordinary workplaces and centres of activity to test for tiny levels of targeted molecu ....ARC Research Hub for Integrated Device for End-user Analysis at Low-levels. ARC Research Hub for Integrated Device for End-user Analysis at Low-levels. This hub aims to improve detection of biological materials by building a portable device for rapid, time-critical detection of low-abundance molecular and cellular analytes. It is expected that the resulting technologies would be used at medical points of care, ordinary workplaces and centres of activity to test for tiny levels of targeted molecules. The initial focus would be early diagnosis of disease and point-of-care drug testing for humans and animals, but the technology platform could be used to sample food and environmental toxins. The hub expects these disruptive technologies will make Australian biotechnology, diagnostics, veterinary, agribusiness and manufacturing firms globally competitive.Read moreRead less
Imaging Mass Spectrometry (IMS), a peptide biomarker discovery tool using tissue. Cancer is the second most common cause of death in Australia. The newly developed technology of Imaging Mass Spectrometry for peptides in tissue has the potential to discover biomarkers for early diagnosis of cancer. This new technology could avoid a number of cancer deaths and reduce suffering of patients through earlier and better diagnosis.
Advanced biosensing in the terahertz (THz) sub-wavelength regime. This project will build on Australian excellence in photonics, exploiting the advanced use of T-rays for sensing of biological substances such as proteins and DNA. For the first time, this will enable contactless automated sensing for high-speed medical screening of diseases, a critical step toward the ultimate vision of customised medicine.
Electrochemical biosensors for detection of cardiac disease markers in blood. Cardiovascular diseases leading to heart failure have a prevalence of over 16 per cent in Australia. The social, economic and health burden is higher than for any other disease group. Hence, it is critically important to develop fit-for-purpose sensors of known cardiac biomarkers, which alert patients and clinicians of the risk of imminent heart failure.
Beyond the diffraction limit: sub-diffraction T-ray biochip sensing using planar metamaterials. T-rays are able to detect small changes in molecular structure and different isomeric and intermolecular configurations. With a comparatively long wavelength (0.3 mm at 1 THz), diffraction limits its use for imaging small biosamples. A method for achieving sub-diffraction sensing, required for biochips, is to adopt near-field techniques. However, due to the small biosample masses, there is a critical ....Beyond the diffraction limit: sub-diffraction T-ray biochip sensing using planar metamaterials. T-rays are able to detect small changes in molecular structure and different isomeric and intermolecular configurations. With a comparatively long wavelength (0.3 mm at 1 THz), diffraction limits its use for imaging small biosamples. A method for achieving sub-diffraction sensing, required for biochips, is to adopt near-field techniques. However, due to the small biosample masses, there is a critical need to enhance the response. This project will investigate a planar metamaterial thin-film T-ray sensor, for a new leap in non-invasive biochip sensing. This outcome will build downstream IP for rapid screening of DNA and proteins for healthcare. The project will also elucidate the science of T-ray interaction with biomaterials at small scales.Read moreRead less
Quantitative multi-modal optical imaging of deep tissue. This project aims to create new tools to quantify the structural and functional properties of tissue. Combining multiple optical imaging technologies (multi-modal) into a single, miniaturised probe, these tools could enable physiologists and biomedical researchers to obtain new insight into disease. Encasing the highly miniaturised probe within a medical needle is aimed to allow insertion of the 'needle probe' deep into tissue, extending o ....Quantitative multi-modal optical imaging of deep tissue. This project aims to create new tools to quantify the structural and functional properties of tissue. Combining multiple optical imaging technologies (multi-modal) into a single, miniaturised probe, these tools could enable physiologists and biomedical researchers to obtain new insight into disease. Encasing the highly miniaturised probe within a medical needle is aimed to allow insertion of the 'needle probe' deep into tissue, extending optical imaging to areas not previously accessible. The project could develop novel quantification models to allow longitudinal assessment and comparison between subjects. Validating the tools with specific biomarkers, it could provide outcomes in breast and liver cancer, and a framework to explore other diseases.Read moreRead less
Industrial Transformation Research Hubs - Grant ID: IH210100040
Funder
Australian Research Council
Funding Amount
$5,000,000.00
Summary
ARC RESEARCH HUB FOR CONNECTED SENSORS FOR HEALTH. This Hub aims to develop, manufacture and deploy high-tech, cyber-secure, medically-certified IoT sensors to global health markets by integrating disparate Australian capabilities into a productive end-to-end value chain. This Hub expects to position Australia at the forefront of connected health by integrating sensor science with cyber-secure data analytics, regulatory approval and certified manufacturing capabilities. Expected outcomes of this ....ARC RESEARCH HUB FOR CONNECTED SENSORS FOR HEALTH. This Hub aims to develop, manufacture and deploy high-tech, cyber-secure, medically-certified IoT sensors to global health markets by integrating disparate Australian capabilities into a productive end-to-end value chain. This Hub expects to position Australia at the forefront of connected health by integrating sensor science with cyber-secure data analytics, regulatory approval and certified manufacturing capabilities. Expected outcomes of this Hub include advanced manufacturing capacity for connected sensors, strategic partnerships and commercialisation skills to translate sensors research to create economic benefits such as jobs and locally-made products for domestic and export markets, as well as improving the health of Australians.Read moreRead less
Development of a diagnostic microarray to detect aneuploidy in single cells. Chromosomal abnormalities account for about 10 per cent of all babies born with a defect. The risk of chromosomal abnormalities increases with maternal age and in patients with fertility problems. It has been estimated that 50 per cent of all embryos are aneuploid. Chromosomal aberrations also occur in the vast majority of tumours in humans. Accurate and rapid detection of chromosomal defects is an important health ser ....Development of a diagnostic microarray to detect aneuploidy in single cells. Chromosomal abnormalities account for about 10 per cent of all babies born with a defect. The risk of chromosomal abnormalities increases with maternal age and in patients with fertility problems. It has been estimated that 50 per cent of all embryos are aneuploid. Chromosomal aberrations also occur in the vast majority of tumours in humans. Accurate and rapid detection of chromosomal defects is an important health service delivered to the Australian public. This project aims to develop better tests for application in prenatal diagnostics including non-invasive testing of fetal cells from maternal circulation or cervical samples at 6-13 weeks gestation, IVF and cancer diagnostics.Read moreRead less
Disruptive approaches to biological sensing. Optical fibre-based biosensors have the potential to transform our ability to monitor our environment, protect our nation's assets and safeguard our citizens, and to offer improved clinical diagnostics and food quality control by creating tools that can detect biomolecules in real-time within complex samples. To fulfil this mission, we propose to develop new fibre-based sensing architectures for sensing biomolecules that have the potential to be sensi ....Disruptive approaches to biological sensing. Optical fibre-based biosensors have the potential to transform our ability to monitor our environment, protect our nation's assets and safeguard our citizens, and to offer improved clinical diagnostics and food quality control by creating tools that can detect biomolecules in real-time within complex samples. To fulfil this mission, we propose to develop new fibre-based sensing architectures for sensing biomolecules that have the potential to be sensitive, selective, fast and compact.Read moreRead less
Pharmacological probes to facilitate preclinical development of modulators of a6 subunit containing nicotinic acetylcholine receptors. Allosteric modulators of alpha7 nicotinic acetylcholine receptors have a promising future as drugs targeting attention deficits in Alzheimer’s disease and schizophrenia but the mechanisms underlying modulation are poorly understood. This project aims to determine its binding site and develop a radioactive labelled compound that competes with its binding. The radi ....Pharmacological probes to facilitate preclinical development of modulators of a6 subunit containing nicotinic acetylcholine receptors. Allosteric modulators of alpha7 nicotinic acetylcholine receptors have a promising future as drugs targeting attention deficits in Alzheimer’s disease and schizophrenia but the mechanisms underlying modulation are poorly understood. This project aims to determine its binding site and develop a radioactive labelled compound that competes with its binding. The radiolabelled compound and a deeper insight into the mode of action will enable development of ligands for positron emission tomography (PET) which will aid in the development of BNC375 as well as other alpha7 modulators.Read moreRead less